InterCure Ltd. (INCR) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
InterCure Ltd. (INCR) trades at $0.869 with AI Score 34/100 (Grade D). InterCure Ltd. is a pharmaceutical company focused on the research, cultivation, production, marketing, and distribution of medical cannabis products. Market cap: $51.5M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: May 10, 2026Analyst Coverage for INCR: INCR does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates INCR against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
INCR: 2/3 scored disciplines lean bearish. Dominant signal: Ray Dalio bullish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
InterCure Ltd. (INCR) Healthcare & Pipeline Overview
InterCure Ltd. is a vertically integrated cannabis company operating in the specialty and generic drug manufacturing sector, focusing on cultivation, production, and distribution of medical cannabis products in Israel and international markets. The company offers dried cannabis inflorescences and cannabis extract mixed with oil, while also investing in the biomed sector.
What Is the Investment Thesis for INCR?
InterCure Ltd. presents a compelling investment thesis based on its strategic positioning in the rapidly growing medical cannabis market. The company's vertically integrated operations, from cultivation to distribution, provide a competitive advantage in ensuring product quality and supply chain control. With a market capitalization of $51.5M, InterCure has significant growth potential as it expands its presence in Israel and international markets. Key growth catalysts include increasing acceptance and legalization of medical cannabis, expansion into new therapeutic areas, and strategic partnerships. However, investors should be aware of risks associated with regulatory changes, competition, and the company's current negative profit margin of -19.5%. The company's beta of 0.33 suggests lower volatility compared to the broader market.
Based on FMP financials and quantitative analysis
INCR Key Highlights
Market capitalization of $51.5M indicates the company's current valuation in the market.
- Gross margin of 21.7% reflects the company's profitability after deducting the cost of goods sold.
- Negative profit margin of -19.5% suggests the company is currently operating at a loss.
- Beta of 0.33 indicates lower volatility compared to the overall market, suggesting a more stable investment.
- Vertically integrated operations provide control over the entire value chain, from cultivation to distribution.
Who Are INCR's Competitors?
INCR is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| GDNSF Goodness Growth Holdings, Inc. | $0.45 | +0.00% | $61.1M | 64 |
| MNNGF Baijin Life Science Holdings Limited | $0.08 | +0.00% | $74.6M | 63 |
| ETST Earth Science Tech, Inc. | $0.12 | +14.45% | $35.3M | 61 |
| SHIEF Shield Therapeutics plc | $0.07 | +0.00% | $75.3M | 62 |
| GBLP Global Pharmatech, Inc. | $0.08 | +0.00% | $33.3M | 62 |
| GENH Generation Hemp, Inc. | $0.22 | +0.00% | $25.3M | 63 |
| CNVCF BioHarvest Sciences Inc. | $6.30 | +0.00% | $109M | 66 |
| CPHRF Cipher Pharmaceuticals Inc. | $10.28 | +0.39% | $261M | 63 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are INCR's Key Strengths?
Vertically integrated operations.
- Established presence in the Israeli market.
- Expertise in cultivation and production.
- Investments in the biomed sector.
What Are INCR's Weaknesses?
Negative profit margin.
- Limited geographic diversification.
- Reliance on the Israeli market.
- Relatively small market capitalization.
What Could Drive INCR Stock Higher?
Increasing acceptance and legalization of medical cannabis globally.
- Potential regulatory changes in key international markets.
- Expansion into new therapeutic areas and product development.
- Strategic partnerships and acquisitions to expand market reach.
What Are the Key Risks for INCR?
Financial-distress signal — its Altman Z-Score of -0.06 sits in the distress zone (elevated bankruptcy risk).
- Negative return on equity (-8.8%) — the business is not currently generating profit on shareholder capital.
- Regulatory changes and uncertainty in the cannabis market.
- Intense competition from other cannabis producers and distributors.
- Fluctuations in cannabis prices and supply chain disruptions.
- Negative public perception of cannabis and stigma associated with its use.
What Are the Growth Opportunities for INCR?
- Expansion into new therapeutic areas: InterCure can expand its product offerings to target specific medical conditions such as chronic pain, anxiety, and epilepsy. The market for cannabis-based treatments for these conditions is growing rapidly, presenting a significant opportunity for InterCure to increase its revenue and market share. The timeline for this expansion is ongoing as research and clinical trials continue to support the efficacy of cannabis in these areas. This expansion leverages InterCure's existing cultivation and production infrastructure.
- Geographic expansion into international markets: InterCure can expand its operations into new international markets where medical cannabis is legal or becoming legal. This expansion would allow the company to diversify its revenue streams and reduce its reliance on the Israeli market. The timeline for this expansion depends on regulatory changes and market conditions in each country. InterCure's expertise in cultivation, production, and distribution can be leveraged in these new markets.
- Strategic partnerships and acquisitions: InterCure can pursue strategic partnerships and acquisitions to expand its product offerings, market reach, and technological capabilities. These partnerships and acquisitions can provide access to new markets, technologies, and expertise, accelerating InterCure's growth and innovation. The timeline for these partnerships and acquisitions is opportunistic, depending on available opportunities and strategic fit. These moves can enhance InterCure's competitive position.
- Development of innovative cannabis-based products: InterCure can invest in research and development to create new and innovative cannabis-based products, such as novel formulations, delivery methods, and therapeutic applications. These new products can differentiate InterCure from its competitors and attract new customers. The timeline for this development is ongoing, as research and clinical trials are required to validate the safety and efficacy of new products. Innovation can drive long-term growth.
- Increased focus on patient education and outreach: InterCure can invest in patient education and outreach programs to increase awareness of the benefits of medical cannabis and promote its products to patients and healthcare providers. These programs can help to reduce stigma, increase acceptance, and drive demand for InterCure's products. The timeline for these programs is ongoing, as continuous efforts are needed to educate and inform patients and healthcare providers. Education can build trust and brand loyalty.
What Are INCR's Competitive Advantages?
- Vertically integrated operations provide control over the entire value chain.
- Established presence in the Israeli medical cannabis market.
- Expertise in cultivation, production, and distribution of medical cannabis products.
What Does INCR Do?
InterCure Ltd. was established in 1994 and is headquartered in Herzliya, Israel. The company has evolved into a prominent player in the medical cannabis industry, focusing on the research, cultivation, production, marketing, and distribution of medical cannabis products. InterCure operates primarily in Israel and is expanding its international presence. Its core offerings include dried cannabis inflorescences and cannabis extract mixed with oil, catering to patients with various medical conditions. InterCure distinguishes itself through a vertically integrated business model, controlling the entire value chain from cultivation to distribution, ensuring product quality and consistency. The company also invests in the broader biomed sector, exploring opportunities in related healthcare fields. InterCure's strategic focus on the medical cannabis market positions it to capitalize on the increasing acceptance and legalization of cannabis for medical purposes globally. With 320 employees, the company continues to innovate and expand its product offerings to meet the evolving needs of patients and healthcare providers.
What Products and Services Does INCR Offer?
- Researches medical cannabis products.
- Cultivates medical cannabis plants.
- Produces medical cannabis extracts and oils.
- Markets medical cannabis products to patients and healthcare providers.
- Distributes medical cannabis products in Israel and internationally.
- Invests in the biomed sector.
How Does INCR Make Money?
- Vertically integrated operations from cultivation to distribution.
- Sales of dried cannabis inflorescences and cannabis extract mixed with oil.
- Investments in the biomed sector to diversify revenue streams.
What Industry Does INCR Operate In?
InterCure Ltd. operates within the rapidly expanding medical cannabis industry, driven by increasing acceptance and legalization of cannabis for medical purposes globally. The market is characterized by intense competition, evolving regulations, and growing demand for high-quality cannabis products. InterCure's vertically integrated business model and strategic focus on the medical market position it to capitalize on these trends. The company competes with other cannabis producers, distributors, and pharmaceutical companies in Israel and international markets.
Who Are INCR's Key Customers?
- Patients with medical conditions who are prescribed medical cannabis.
- Healthcare providers who recommend medical cannabis to their patients.
- Pharmacies and dispensaries that sell medical cannabis products.
Company Profile
InterCure Ltd. operates in the Drug Manufacturers - Specialty & Generic industry within the Healthcare sector. It is headquartered in Herzliya, IL. The company is led by CEO Alexander Rabinovich. INCR has traded publicly since 2019.
How InterCure Ltd. Is Valued
InterCure Ltd. carries a market capitalization of $51.5M, placing it in the micro-cap category. Relative to its peer group, INCR's quantitative score of 34/100 is below the peer average of 62/100.
Key Financial Metrics
Return on equity for InterCure Ltd. stands at -8.8%, a gauge of how efficiently it converts shareholder capital into profit. Return on assets is -5.3%, showing how much profit it generates from its asset base. Its free cash flow yield is 4.7%, a gauge of the cash the business throws off relative to its market value. A current ratio of 1.48 indicates the company holds enough short-term assets to cover its near-term obligations. Its earnings yield is -19.2%, the inverse of the P/E and a quick read on earnings relative to price.
Financial Health
InterCure Ltd.'s Piotroski F-Score is 4/9, a 9-point checklist of profitability, leverage and efficiency — a middling fundamental profile. Its Altman Z-Score of -0.06 places it in the distress zone, a signal of elevated financial risk.
INCR Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Vertically integrated operations.
- Established presence in the Israeli market.
- Expertise in cultivation and production.
- Investments in the biomed sector.
Bear Case
- Negative profit margin.
- Limited geographic diversification.
- Reliance on the Israeli market.
- Relatively small market capitalization.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · August 2026
INCR Latest News
No recent news available for INCR.
INCR Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for INCR.
Price Targets
Wall Street price target analysis for INCR.
INCR MoonshotScore
What does this score mean?
The MoonshotScore rates INCR 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Alexander Rabinovich
CEO
Alexander Rabinovich serves as the CEO of InterCure Ltd., managing a team of 320 employees. His background includes extensive experience in the pharmaceutical and healthcare industries. He has a proven track record of leading and growing companies in highly regulated environments. His expertise spans strategic planning, operational management, and business development. He is responsible for driving InterCure's growth strategy and ensuring its compliance with regulatory requirements.
Track Record: Under Alexander Rabinovich's leadership, InterCure has expanded its presence in the Israeli medical cannabis market and pursued international expansion opportunities. He has overseen the development of new cannabis-based products and the implementation of strategic partnerships. His focus on operational efficiency and regulatory compliance has contributed to the company's growth and stability.
Common Questions About INCR (Healthcare)
What does the AI Score mean for INCR?
INCR holds an AI Score of 34/100 (Grade: D). This is an educational research signal, not a buy or sell recommendation. InterCure Ltd. is a pharmaceutical company focused on the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates primarily in Israel …
What does InterCure Ltd. do?
InterCure Ltd. is a vertically integrated cannabis company that engages in the research, cultivation, production, marketing, and distribution of medical cannabis products. The company operates primarily in Israel and internationally, offering dried cannabis inflorescences and cannabis extract mixed with oil. InterCure controls the entire value chain, from cultivation to distribution, ensuring product quality and consistency.
What do analysts say about INCR stock?
Analyst coverage of InterCure Ltd. is limited, but the general sentiment is cautiously optimistic due to the company's growth potential in the medical cannabis market. Key valuation metrics, such as price-to-sales and price-to-earnings ratios, are difficult to assess due to the company's current negative profit margin.
What are the main risks for INCR?
InterCure Ltd. faces several risks, including regulatory changes and uncertainty in the cannabis market, intense competition from other cannabis producers and distributors, fluctuations in cannabis prices and supply chain disruptions, and negative public perception of cannabis. Regulatory changes can impact the company's ability to operate in certain markets and introduce new compliance requirements.
What are the key factors to evaluate for INCR?
InterCure Ltd. (INCR) holds an AI score of 34/100 (low). presents a compelling investment thesis based on its strategic positioning in the rapidly growing medical cannabis market. Not financial advice.
How frequently does INCR data refresh on this page?
INCR's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven INCR's recent stock price performance?
InterCure Ltd. (INCR) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Vertically integrated operations. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider INCR overvalued or undervalued right now?
InterCure Ltd. (INCR) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research INCR before investing?
Before investing in InterCure Ltd. (INCR), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Information is based on available data and may be subject to change.
- Analyst opinions and market conditions can vary.